SDAI Reshapes Top Leadership as Subsidiary Chief Liu Ting Becomes Group CEO

An update from SDAI ( (SG:5TI) ) is now available.

SDAI Limited has reshuffled its top leadership, appointing current group CEO Yap Koon Loong as an executive director of the board while he relinquishes his role as chief executive, and elevating Liu Ting, CEO of wholly owned subsidiary Hainan Blue Code Biotechnology, to group CEO effective 16 January 2026. The move strengthens board-level executive representation and promotes leadership from within its biotechnology operations, while the overall board composition and key governance committees, including audit, remuneration, nominating and risk committees, remain unchanged, signalling continuity in oversight alongside the management transition.

More about SDAI

SDAI Limited is a Singapore-incorporated holding company listed on Catalist, operating through subsidiaries including Hainan Blue Code Biotechnology Co., Ltd., indicating a business presence in the biotechnology sector in China.

Current Market Cap: S$33.97M

For a thorough assessment of 5TI stock, go to TipRanks’ Stock Analysis page.